NYSE:DPLO

Diplomat Pharmacy (DPLO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.00
$4.01
50-Day Range
$4.00
$4.00
52-Week Range
$2.43
$14.46
Volume
744,968 shs
Average Volume
545,194 shs
Market Capitalization
$304 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DPLO stock logo

About Diplomat Pharmacy Stock (NYSE:DPLO)

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

DPLO Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
My top 100 stocks…
We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.
Diplomat Cocktail
See More Headlines
Receive DPLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diplomat Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
4/26/2024

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Fax
N/A
Employees
2,335
Year Founded
N/A

Profitability

Net Income
$-302,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.49 billion
Cash Flow
$4.60 per share
Book Value
$6.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$304 million
Optionable
Optionable
Beta
0.82
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Brian Thomas Griffin (Age 60)
    CEO & Chairman
  • Mr. Philip R. Hagerman (Age 67)
    Co-Founder & Chairman Emeritus
  • Mr. Daniel Paul Davison
    CFO & Treasurer
  • Mr. Dave Loschinskey (Age 48)
    Chief Operating Officer
  • Ms. Terri Anne Powers
    VP of Investor Relations

DPLO Stock Analysis - Frequently Asked Questions

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing the consensus estimate of ($0.20) by $2.15. The company earned $1.30 billion during the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a negative net margin of 12.47% and a negative trailing twelve-month return on equity of 12.15%. The firm's revenue for the quarter was down 5.3% on a year-over-year basis.

What other stocks do shareholders of Diplomat Pharmacy own?
This page (NYSE:DPLO) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners